Late-Breaking Abstracts

The SITC Annual Meeting showcases highly significant timely findings, ground-breaking data and high impact results. Scientists that had late-breaking, original research to present at a top scientific venue, were encouraged to submit their research during the late-breaking abstract submission period.

Both SITC members and nonmembers were encouraged to submit a late-breaking abstract FREE of cost, to be considered for an oral presentation at the SITC 28th Annual Meeting. The abstract selection committee places particular emphasis on selecting abstracts describing up-to-date clinical trial results or novel basic tumor immunology data.

Late-Breaking Abstract Submission Categories Included:

  • Adoptive Immunotherapy
  • Antibody Recognition to Engage Cells of the Innate and Adaptive Immune Systems (Antibody Dependent Cell-Mediated Cytotoxicity: ADCC)
  • Biomarkers and Immunoscoring
  • Combination Approach in Cancer
  • Immune Monitoring
  • Immunotherapy in Combination with Radiation Therapy
  • Metabolism and Immunity
  • Novel Agents for Delivering Immunotherapy
  • The Impact of Systems Biology on Immunotherapy
  • Tumor Escape, Immune Editing and Role of Immune System in Preventing Oncogenesis
  • Tumor Immune Resistance and Overcoming It
  • Tumor Microenvironment and Innate Cells Recognition
  • Vaccines

Guidelines for Authors

Authors submitting Late-Breaking abstracts to the SITC 28th Annual Meeting agreed to the following:

  • Serve as the contact for all correspondence about the abstract and inform co-authors about its status
  • Confirm all authors are aware of and agree to the content and data presented in the abstract
  • Verify the abstract is accurate and that permission has been obtained from all relevant parties
  • Verify the data presented in the abstract has not been pub­lished in whole or in part prior to the SITC 28th Annual Meeting
  • Agree that abstracts submitted to SITC 28th Annual Meeting are embargoed until 8:00 am Central on November 7, 2013
  • Agree that, if accepted, they or a co-author will present the abstract at the Annual Meeting

Each abstract is limited to 3,000 characters. Title, authors, institutions, abstract body, spaces, tables, and images are included in this count.

SITC Quick Links

Program presentations are now available through the "schedule" section of individual programs!

Connect with SITC!

Support Information

Thank you to all SITC 2013 supporters!

Confirm your support for SITC's 2014 programs today! Click here for more information.

Annual Meeting Supporters




Prometheus Laboratories


Celgene Corporation
Provectus Pharmaceuticals


Argos Therapeutics

Center for Cancer Research
National Cancer Institute
National Institutes of Health
Department of Health and Human Services

Immuneering Corporation

Lonza Walkersville


Prima BioMed